JPX:4570
Immuno-Biological Laboratories Co., Ltd. · JPX · Healthcare · JPY · FY for 2026
Figures on this page computed 2026-11-08 13:29 UTC
Last close
n/aJPY
Market data
25.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- computed
- Computed from the filing for 2026
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
32.7%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
26.6%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- JPY
- computed
Price is the furthest below its sector's middle: 0.24 against 0.37 on the market's range.
- Growth10.8%61 of 100, above its sector
- Returns on capital17.9%89 of 100, above its sector
- Margins69.7%91 of 100, above its sector
- Price25.9x24 of 100, below its sector
- Safety5.6892 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
All from 100
lens 2 of 9Sales
174Shares in issue
106- Profit, where the first year is 100: n/aNot enough filed years carry this line for it to be drawn. No line is drawn flat in its place.
Sales is at 174, Shares in issue is at 106, against 100 in 2020.
Sales is at 174, Shares in issue is at 106, against 100 in 2020.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2026
Sales, where the first year is 100175
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY
Profit, where the first year is 100n/a
Not held.
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY
Shares in issue, where the first year is 100106
- Source
- computed
- Statement
- income
- Fiscal year
- 2026
- Reported in
- JPY